Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

AWARE Intervention: Feasibility and Efficacy Trial at Three University Health Services Centers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03961633
Recruitment Status : Completed
First Posted : May 23, 2019
Last Update Posted : May 23, 2019
Sponsor:
Collaborator:
Harvard University
Information provided by (Responsible Party):
Hyeouk Hahm, Boston University Charles River Campus

Brief Summary:

The goal of this study is to test the efficacy and the feasibility of the Asian Women's Action for Resilience and Empowerment (AWARE) intervention, in the real world setting -- student health service centers at Boston University, Wellesley College, and Harvard University.

AWARE is an 8-week group intervention specifically designed to address mental health and sexual health issues among Asian-Pacific Islander (API) women. One AWARE group (final number of 8-10 API women who will be treated) will be held at BU Student Health Services, two groups at Wellesley College, and two groups at Harvard University Health Services for undergraduate and graduate students who meet the demographic and clinical criteria.

During the intervention period, participants will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. Participants will fill out forms that detail their therapeutic goals ("commitments") and any adverse emotional/behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes.

Participants will be assessed pre- and post-intervention on clinical outcomes, including depression, anxiety, PTSD, and suicidality, using standardized quantitative instruments. This serves to evaluate the efficacy of AWARE at improving mental health outcomes. Participants will also participate in a post-intervention focus group session to evaluate the program's implementation and suggest ways for future improvement.


Condition or disease Intervention/treatment Phase
Depression Anxiety PTSD Suicidal Ideation Substance Use Disorders Unsafe Sex Coping Behavior Behavioral: AWARE intervention Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Participants are assigned to a single intervention ("treatment") group. Intervention at the two sites are not concurrent; the Boston University site intervention takes place in March - May 2018, and the Harvard University site intervention takes place in October - December 2018.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Asian Women's Action for Resilience and Empowerment (AWARE) Intervention: Feasibility and Efficacy Trial at Three University Health Services Centers
Actual Study Start Date : August 1, 2016
Actual Primary Completion Date : December 10, 2018
Actual Study Completion Date : February 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Experimental: AWARE intervention
This arm is the "treatment group", which receives the intervention, and is the only arm in the study. See the "intervention" column for more descriptions.
Behavioral: AWARE intervention

will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the "Study Description - Detailed Description" section.

Participants will fill out forms that detail their therapeutic goals ("commitments") and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes.





Primary Outcome Measures :
  1. Change in depression symptoms [ Time Frame: Pre/post-intervention (within 4 weeks prior / within 1 week following intervention) ]
    Change in depression symptoms measured by the Center for Epidemiologic Studies Depression Scale - Revised (CESD-R). The CESD-R scoring scale ranges from 0 (no depression) to 80 (severe depression), and 16 or higher is the threshold for clinical depression diagnosis.

  2. Change in anxiety symptoms [ Time Frame: Pre/post-intervention (within 4 weeks prior / within 1 week following intervention) ]
    Change in depression symptoms measured by the Hospital Anxiety and Depression Scale (HADS). The HADS scoring scale ranges from 0 (no anxiety) to 21 (severe anxiety), and 11 or higher is the threshold for clinical anxiety disorder diagnosis.

  3. Change in PTSD symptoms [ Time Frame: Pre/post-intervention (within 4 weeks prior / within 1 week following intervention) ]
    Change in PTSD symptoms measured by the PTSD Checklist - Civilian Version (PCL-C). The PCL-C scoring scale ranges from 1 (no PTSD symptoms) to 85 (severe PTSD symptoms), and 30 or higher is the threshold for clinical PTSD diagnosis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Anyone who self-identifies as an "(Asian American) woman".
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria -- participants must meet all of the following:

  1. 18 - 35 years old;
  2. Identify as Asian American females;
  3. Single (unmarried);
  4. Have a mobile phone with a text messaging plan;
  5. Having depressive symptoms (CESD-R score equal to or greater than 16), or clinical anxiety (HADS-A score equal to or greater than 11), or PTSD symptoms (PCL-C score equal to or greater than 30), or exposure to physical or sexual violence during childhood (assessed using the ACE-IQ).

Exclusion Criteria -- participants who meet any of the following:

  1. Actively suicidal and homicidal (assessed using C-SSRS);
  2. Participants who show psychotic symptoms such as visual or auditory hallucinations;
  3. Students at the trial facilities who are currently members of the research team.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03961633


Locations
Layout table for location information
United States, Massachusetts
Boston University Student Health Services
Boston, Massachusetts, United States, 02215
Harvard University Health Services
Cambridge, Massachusetts, United States, 02138
Sponsors and Collaborators
Boston University Charles River Campus
Harvard University
Investigators
Layout table for investigator information
Principal Investigator: Hyeouk C Hahm, PhD, LCSW Boston University School of Social Work
Layout table for additonal information
Responsible Party: Hyeouk Hahm, Associate Professor, Chair of Social Research, Boston University Charles River Campus
ClinicalTrials.gov Identifier: NCT03961633    
Other Study ID Numbers: 4755
First Posted: May 23, 2019    Key Record Dates
Last Update Posted: May 23, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Suicidal Ideation
Behavioral Symptoms
Chemically-Induced Disorders
Mental Disorders
Suicide
Self-Injurious Behavior